Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Tax Provisions (2021 - 2025)

Aytu Biopharma (AYTU) has disclosed Tax Provisions for 6 consecutive years, with $437000.0 as the latest value for Q2 2025.

  • Quarterly Tax Provisions fell 48.1% to $437000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $315000.0 through Dec 2025, down 78.79% year-over-year, with the annual reading at $437000.0 for FY2025, 79.6% down from the prior year.
  • Tax Provisions for Q2 2025 was $437000.0 at Aytu Biopharma, up from -$122000.0 in the prior quarter.
  • The five-year high for Tax Provisions was $842000.0 in Q2 2024, with the low at -$283000.0 in Q4 2024.
  • Average Tax Provisions over 5 years is $248454.5, with a median of $126000.0 recorded in 2023.
  • Peak annual rise in Tax Provisions hit 568.25% in 2024, while the deepest fall reached 135.37% in 2024.
  • Over 5 years, Tax Provisions stood at -$3000.0 in 2021, then soared by 4000.0% to $117000.0 in 2022, then skyrocketed by 583.76% to $800000.0 in 2023, then plummeted by 135.38% to -$283000.0 in 2024, then skyrocketed by 254.42% to $437000.0 in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at $437000.0, -$122000.0, and -$283000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.